Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
CORXEL Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.
Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
Tenaya Therapeutics a clinical-stage biotechnology company that develops novel therapies to treat heart diseases.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
Belite Bio is a clinical stage biopharmaceutical drug development company.
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
RTW Investments has invested in 107 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RTW Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.
Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. RTW Investments's total known invested capital is $11.5B.
RTW Investments's average investment size is $139.0M across its portfolio of 107 companies.
Recent RTW Investments portfolio additions include Prolium, Immunic Therapeutics, Evommune, CORXEL Pharmaceuticals, Ocugen. These companies were founded in 2020 or later.